TB-500 (Thymosin Beta-4) Research Guide 2026: Healing, Recovery, and Cost Analysis

Introduction to TB-500

TB-500 is a synthetic peptide derived from Thymosin Beta-4 (Tβ4), a naturally occurring protein found in virtually every nucleated cell in the human body. As the most abundant member of the beta-thymosin family, Thymosin Beta-4 plays indispensable roles in cellular homeostasis, tissue repair, and regenerative biology. TB-500 represents a specific fragment of this larger protein — the active amino acid sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES — selected for its potent bioactivity and research utility.

For dosing, reconstitution, and protocol details, see our TB-500 Dosage Guide: Thymosin Beta-4 Research Protocols & Reconstitution (2026).

The peptide first attracted serious scientific interest in the early 1990s when researchers identified it as the principal intracellular G-actin sequestering molecule in mammalian cells. Since then, the body of preclinical and early clinical evidence has expanded dramatically, with studies examining TB-500's roles in wound closure, cardiac regeneration, musculoskeletal repair, neurological recovery, hair follicle activation, and anti-inflammatory signaling.

With approximately 30,000 monthly searches, TB-500 sits at the intersection of cutting-edge regenerative peptide research and widespread scientific curiosity. This article presents a thorough review of its chemistry, mechanisms, research evidence, dosing protocols studied in research settings, and safety considerations.

> Research Disclaimer: All information presented here is for educational purposes only. TB-500 is an unapproved research peptide and is not cleared by the FDA or other regulatory bodies for therapeutic use in humans. This content does not constitute medical advice. Consult a licensed healthcare provider before considering any peptide-based intervention.

---

What Is Thymosin Beta-4? Origins and Biology

Thymosin Beta-4 is a 43-amino acid, 4.9 kDa peptide encoded by the TMSB4X gene on the X chromosome. It belongs to the beta-thymosin family, a group of intrinsically disordered proteins characterized by their ability to bind monomeric actin (G-actin) with high affinity.

Originally isolated from bovine thymus tissue in the 1960s by Allan Goldstein and colleagues, Thymosin Beta-4 was initially studied for its immune-modulating properties. However, as molecular biology advanced, researchers discovered that its expression is ubiquitous — present in platelets, macrophages, endothelial cells, cardiac progenitor cells, neurons, and epithelial tissues. This near-universal distribution suggested a fundamental, conserved biological role beyond thymic immunity.

The peptide's most critical property is its capacity to maintain an intracellular reservoir of unpolymerized actin. In resting cells, Thymosin Beta-4 sequesters roughly 40–50% of the total G-actin pool, keeping it in a state ready for rapid mobilization when cells receive signals to migrate, proliferate, or repair damaged tissue.

TB-500, as the synthetic research analog, replicates this bioactivity. Its shorter sequence confers stability, cell permeability, and ease of synthesis while preserving the functional interaction with G-actin and downstream signaling cascades.

---

Chemical Properties and Molecular Structure

Understanding TB-500's molecular characteristics provides important context for interpreting research findings:

• •Molecular formula: C₂₁₂H₃₅₀N₅₆O₇₈S
• •Molecular weight: Approximately 4,963 Da
• •Amino acid sequence: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
• •Isoelectric point (pI): ~5.1, conferring slight negative charge at physiological pH
• •Solubility: Readily soluble in bacteriostatic water or acetic acid
• •Storage: Lyophilized powder is stable at -20°C for 24+ months; reconstituted solutions should be refrigerated and used within 14 days

As an intrinsically disordered protein, TB-500 lacks a fixed tertiary structure in solution. This structural flexibility is functionally important — it allows the peptide to interact with multiple binding partners and adopt different conformational states depending on the cellular microenvironment. The LKKTET motif within the sequence is particularly significant, serving as the primary actin-binding domain that mediates G-actin sequestration.

---

Mechanism of Action

TB-500's biological effects emerge from several interconnected molecular mechanisms, each contributing to the peptide's regenerative and anti-inflammatory profile.

Actin Regulation and Cell Motility

The most thoroughly characterized mechanism involves the sequestration of monomeric G-actin. The cytoskeleton — the dynamic scaffolding within cells — depends on the precise balance between polymerized F-actin filaments and the unpolymerized G-actin pool. TB-500 binds G-actin monomers with high affinity, maintaining a readily available reserve that cells can rapidly deploy when migration or structural remodeling is required.

When cells receive signals to migrate toward a wound or injury — triggered by chemokines, growth factors like VEGF, or mechanical cues — TB-500 releases its bound actin monomers to profilin, which catalyzes nucleotide exchange (GDP to GTP). These activated actin monomers are then directed to the growing ends of filaments, extending lamellipodia and filopodia — the cellular projections that physically drive cell movement.

This mechanism underpins many of TB-500's observed effects in research models: faster wound closure, accelerated cell migration to sites of tissue damage, and enhanced remodeling of the extracellular matrix (Sosne & Ousler, Expert Opin Biol Ther, 2012, PMID: 22074294).

Angiogenesis Promotion

TB-500 is a potent promoter of new blood vessel formation. In preclinical models, it upregulates vascular endothelial growth factor (VEGF) and interacts with the VEGF receptor signaling axis, stimulating endothelial cell migration and proliferation. New capillary networks are essential for tissue repair — without adequate blood supply, regenerating tissue cannot receive sufficient oxygen and nutrients, and removal of metabolic waste is impaired.

In cardiac injury models, this angiogenic activity is particularly significant. Studies have shown that TB-500 stimulates the formation of new coronary vasculature following ischemic events, contributing to functional recovery that extends beyond simple inflammation reduction.

Anti-Inflammatory Signaling

TB-500 exerts multi-level anti-inflammatory effects. Research has demonstrated its ability to:

• •Downregulate pro-inflammatory cytokines: Including TNF-α, IL-1β, and IL-6, the primary drivers of acute and chronic inflammatory cascades
• •Modulate NF-κB signaling: NF-κB is the master transcription factor governing inflammatory gene expression; TB-500 appears to inhibit its nuclear translocation in certain cell types
• •Promote M2 macrophage polarization: Macrophages exist on a spectrum from pro-inflammatory (M1) to pro-repair (M2). TB-500 has been shown to shift this balance toward the anti-inflammatory, tissue-remodeling M2 phenotype
• •Reduce immune cell infiltration: In wound models, TB-500-treated tissue shows decreased neutrophil accumulation, reducing the collateral damage associated with excessive inflammatory responses

This anti-inflammatory profile is complementary to — and mechanistically distinct from — BPC-157's anti-inflammatory effects, which primarily operate through the nitric oxide pathway.

Cell Survival and Anti-Apoptotic Effects

Beyond migration and inflammation, TB-500 promotes cell survival under stress conditions. Research indicates that it activates the PI3K/Akt survival pathway, which inhibits pro-apoptotic signaling cascades triggered by ischemia, oxidative stress, or cytotoxic insults. This mechanism is particularly relevant to cardiac and neurological applications, where preserving vulnerable cells during acute injury is paramount.

Stem Cell Activation

One of the most exciting aspects of TB-500 research involves its interaction with tissue-resident progenitor and stem cell populations. Studies have shown that Thymosin Beta-4 promotes the migration of resident stem cells to injury sites and can reactivate quiescent progenitor cells. In the heart, this involves the activation of epicardial progenitor cells that normally remain dormant in adult tissue.

---

Research Evidence by Application

Wound Healing

The wound healing evidence for TB-500 and its parent compound Thymosin Beta-4 is among the most mature in the literature.

A landmark study published in the Journal of Cell Science demonstrated that topical or intraperitoneal administration of Thymosin Beta-4 increased reepithelialization in rat full-thickness wound models by 42% compared to controls at 4 days post-wounding, and by up to 61% at 7 days. Treated wounds also showed significantly increased collagen deposition, improved angiogenesis, and more organized extracellular matrix architecture — consistent with earlier work showing the actin-binding domain of Thymosin Beta-4 promotes dermal repair in diabetic and aged mouse models (Malinda et al., Wound Repair Regen, 2003, PMID: 12581423).

A Phase II clinical trial (NCT00832091) evaluated Thymosin Beta-4 in patients with chronic venous stasis ulcers — wounds notorious for their refractoriness to conventional treatment. The results indicated a statistically significant acceleration in wound closure rate, with 25% of treatment-arm patients achieving complete healing within the study period. Histological analysis revealed that treated wounds contained more mature, tightly organized collagen fiber networks compared to the disorganized arrangement seen in controls.

Research from 2024 introduced an important nuance: a study examining the active metabolite Ac-LKKTE (the N-terminal tetrapeptide of TB-500) found that this degradation product may be the primary mediator of wound healing activity, while the parent TB-500 fragment itself showed reduced direct activity. This finding has implications for understanding bioavailability and optimizing delivery strategies.

Cardiac Repair and Cardioprotection

The cardiac regeneration research on Thymosin Beta-4 is particularly compelling and has attracted attention from major academic medical centers.

Studies from Willoughby and colleagues established that systemic administration of Thymosin Beta-4 in mouse myocardial infarction models simultaneously promoted cardiomyocyte survival, stimulated coronary angiogenesis, and — most remarkably — reactivated dormant epicardial progenitor cells. This last finding suggests that the peptide can partially recapitulate embryonic cardiac development programs in adult tissue.

Mechanistically, TB-500 reduces infarct size by inhibiting caspase-3-mediated cardiomyocyte apoptosis in the ischemic border zone, the region of viable but stressed cells surrounding the infarcted core. Reducing death in this zone preserves cardiac muscle mass and maintains pumping function.

Cardiac functional parameters in treated animals — including ejection fraction, fractional shortening, and end-diastolic volumes — showed statistically significant improvements compared to vehicle-treated controls, with effects persisting at 12-week follow-up assessments.

The compound also demonstrated synergistic effects when combined with conventional post-MI therapies in preclinical models, suggesting potential as an adjunct rather than replacement for standard care.

Musculoskeletal Research: Muscle, Tendon, and Ligament

TB-500's effects on musculoskeletal tissue have been studied across multiple injury models:

Skeletal Muscle: In rodent models of contusion and laceration injury, Thymosin Beta-4 administration accelerated satellite cell (muscle stem cell) proliferation, enhanced myofiber regeneration, and reduced fibrotic scar tissue formation. The anti-fibrotic effect is clinically significant — excessive scar tissue impairs muscle function and increases re-injury risk.

Tendon Repair: Studies using Achilles tendon injury models in rats demonstrated that Tβ4-treated subjects showed significantly improved tendon strength as measured by maximum load-to-failure testing, compared to untreated controls. Histological analysis revealed superior collagen organization — more parallel fiber alignment — in treated tendons, which directly correlates with mechanical function.

Ligament Healing: Preclinical models of medial collateral ligament injury showed accelerated healing timelines and improved ligament histology in TB-500-treated subjects, with collagen maturity scores suggesting more complete structural restoration.

Anti-Fibrotic Activity: A 2018 study found that TB-500 demonstrated antifibrotic properties in a model of alcoholic liver injury, significantly reducing collagen deposition and stellate cell activation. While the liver is not a classical musculoskeletal target, the underlying anti-fibrotic mechanism is relevant across tissue types.

Hair Growth Research

A 2015 study published in FASEB Journal confirmed that Thymosin Beta-4 promotes hair follicle activation and hair growth by interacting with hair follicle stem cells. The peptide was shown to:

• •Accelerate the transition from the telogen (resting) phase to the anagen (active growth) phase of the hair follicle cycle
• •Promote migration of bulge-region stem cells toward the dermal papilla
• •Enhance extracellular matrix remodeling within the follicular niche

The mechanism involves both the actin-regulatory activity (driving stem cell migration) and growth factor signaling (upregulating the stem cell niche factors KGF and VEGF). While research in this area is predominantly preclinical, the findings have generated interest in TB-500 as a potential adjunct in alopecia research.

Neurological Research

Emerging evidence suggests TB-500 may have neuroprotective and neuroregenerative properties:

Spinal Cord Injury: Animal models of spinal cord contusion showed that Thymosin Beta-4 administration reduced secondary neuronal loss, decreased reactive gliosis (the formation of inhibitory glial scars), and improved behavioral recovery scores. The proposed mechanisms include both direct anti-apoptotic effects on neurons and indirect effects via enhanced vascularization of the injured spinal cord.

Stroke: In focal ischemia models, TB-500 reduced infarct volume when administered within a therapeutic window post-injury. Treated animals showed improved performance on behavioral assessments including rotarod and grip strength tests, correlating with greater neuronal preservation in the ischemic penumbra.

Inflammation-Driven Neurodegeneration: Research into Thymosin Beta-4's modulation of microglial activation — the brain's resident immune cells — suggests potential applications in neuroinflammatory conditions. By shifting microglial polarization toward the neuroprotective M2 phenotype, the peptide may help limit secondary damage from sustained neuroinflammation.

Ocular Applications: Studies from the Mohan and Bhatt laboratories demonstrated that Thymosin Beta-4 promotes corneal wound healing through mechanisms overlapping with its systemic wound healing activity, including activation of corneal progenitor cells and anti-inflammatory cytokine modulation. This has prompted interest in topical ocular formulations.

---

Dosing Protocols in Research Settings

The following reflects dosing approaches used in published preclinical and early-phase clinical research. This information is provided for scientific literacy only and does not constitute a clinical recommendation.

Common Research Protocols

In rodent studies, intraperitoneal doses range from 1 mg/kg to 10 mg/kg, with subcutaneous administration also used. Scaling these figures to human-equivalent doses (HED) using FDA standard conversion factors suggests approximate human ranges of 0.2–1.6 mg/kg, though direct extrapolation from animal models has significant limitations.

The human venous ulcer clinical trial used a 0.03% topical formulation applied directly to wounds, which is not comparable to systemic administration.

For systemic research protocols documented in the literature and research community, the most commonly cited parameters are:

Loading Phase (Weeks 1–4):

• •Dose: 2–5 mg per administration
• •Frequency: 2–3 times per week
• •Route: Subcutaneous injection

Maintenance Phase (Weeks 5–12):

• •Dose: 2–2.5 mg per administration
• •Frequency: 1–2 times per week
• •Route: Subcutaneous injection

Cycle Duration: Research protocols typically run 4–12 weeks depending on the injury or research endpoint being evaluated.

Reconstitution

TB-500 is typically supplied as a lyophilized (freeze-dried) powder. Research protocols specify reconstitution with bacteriostatic water (0.9% benzyl alcohol in sterile water) to achieve the desired concentration. A common reconstitution ratio uses 1–2 mL bacteriostatic water per 5 mg vial, yielding 2.5–5 mg/mL solutions.

Important Caveats

Research dosing parameters should not be interpreted as clinical guidance. The optimal human dose — if any safe, effective therapeutic application is eventually established — would be determined through rigorous clinical trials. Individual pharmacokinetics, the specific condition being studied, and compound purity all significantly affect the appropriate research protocol.

---

Safety Profile and Adverse Event Considerations

Clinical Safety Data (Thymosin Beta-4)

Clinical trials evaluating the parent compound Thymosin Beta-4 have consistently reported an acceptable short-term safety profile. The Phase II venous ulcer trial and other studies enrolling hundreds of patients reported predominantly mild, transient adverse events. No serious adverse events were clearly attributed to the peptide in controlled research settings.

TB-500 Specifically: Key Limitations

TB-500 is not approved by the FDA and has not completed formal Phase I safety trials in humans. The safety data for TB-500 specifically cannot be directly extrapolated from Thymosin Beta-4 studies due to structural differences, though TB-500 is derived from the same protein and shares its core bioactive domain.

Commonly Reported Effects in Research Settings

Based on clinical research documentation and reports from research subjects, the following have been noted:

• •Injection site reactions: Mild redness, transient swelling, minor bruising at the injection site — typically resolving within 24–48 hours
• •Headache: Mild to moderate, predominantly in the first 1–2 weeks, likely related to vasodilatory and VEGF-mediated effects
• •Lethargy/fatigue: Transient tiredness reported in a subset of subjects during the initial loading phase
• •Flu-like symptoms: Low-grade malaise, mild nausea — usually self-limiting within the first week

Theoretical Concerns

Several theoretical safety concerns exist that warrant consideration in research design:

Oncological Considerations: Because TB-500 promotes angiogenesis and cell survival signaling (PI3K/Akt), theoretical concern exists regarding potential tumor promotion or acceleration in subjects with occult malignancy. Preclinical data have not established an oncogenic effect at research doses, but long-term human data are absent.

Cardiovascular Effects: The angiogenic activity of TB-500 could theoretically affect atherosclerotic plaque stability or contribute to pathological angiogenesis in conditions like proliferative diabetic retinopathy. These remain theoretical concerns not confirmed in preclinical safety studies.

Quality and Purity Variability: Unlike pharmaceutical-grade compounds, research peptides are subject to significant batch-to-batch variability. Potential contaminants include endotoxins (causing immune reactions), truncated sequences (with unpredictable bioactivity), residual solvents, heavy metals, and microbial contamination. Source verification, third-party certificate of analysis review, and HPLC purity confirmation (≥98%) are essential in any research context.

Regulatory Status

TB-500 is classified as a research chemical in the United States and most other jurisdictions. It is not approved for therapeutic use and is listed as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of Peptide Hormones, Growth Factors, and Related Substances.

---

TB-500 vs BPC-157: Complementary Mechanisms

Researchers frequently study TB-500 alongside BPC-157, as the two peptides operate through mechanistically distinct but complementary pathways, potentially offering synergistic tissue repair activity.

For a detailed mechanistic comparison of these two peptides, see our comprehensive review at /learn/bpc-157-vs-tb-500-regenerative-peptides-compared.

---

Current Research Landscape and Future Directions

The TB-500 research field is active across several fronts:

Ocular Medicine: RegeneRx Biopharmaceuticals has advanced TB4-based formulations (RGN-259) through Phase III clinical trials for neurotrophic keratopathy, a condition of corneal nerve damage causing chronic ulceration. Results from these trials represent some of the most rigorous clinical evidence for the therapeutic potential of Thymosin Beta-4-derived compounds, building on earlier characterization of Thymosin Beta-4 as a corneal wound-healing and anti-inflammatory agent (Sosne et al., Clin Ophthalmol, 2007, PMID: 19668473) and its broader translational path from bench to bedside in ophthalmology (Sosne, Expert Opin Biol Ther, 2018, PMID: 30063853).

Cardiac Regenerative Medicine: Ongoing preclinical and early-phase work is investigating optimized delivery systems — including intramyocardial injection and nanoparticle-mediated delivery — to maximize cardiac progenitor cell activation post-infarction.

Combination Approaches: Research is increasingly evaluating TB-500 in combination with other peptides, growth factors, and cell therapies to determine synergistic dosing strategies. The theoretical complementarity with BPC-157, in particular, has prompted combination protocol investigations.

Biomarker Development: One challenge limiting clinical translation is the absence of validated biomarkers for TB-500 activity. Research teams are working to identify measurable surrogates — including actin dynamics, serum VEGF levels, and macrophage polarization markers — that could serve as pharmacodynamic endpoints in human trials.

Active Metabolite Research: The 2024 finding that Ac-LKKTE (a metabolite of TB-500) may drive wound healing activity has opened a new research avenue focused on understanding the metabolic fate of TB-500 and whether optimizing for active metabolite production could improve therapeutic outcomes.

---

Research Tools and Resources

For researchers working with TB-500, several practical considerations apply:

• •Peptide Calculator: Use our Peptide Dosing Calculator to calculate reconstitution volumes, concentration adjustments, and dosing conversions for preclinical research applications.

• •Product Information: View supplier information and purity certificates for TB-500 research peptides at Peptides.SO TB-500.

• •Comparative Research: For studies evaluating TB-500 alongside BPC-157, our detailed mechanistic comparison provides side-by-side analysis of both compounds' research profiles: BPC-157 vs TB-500 Comparison.

---

Summary

TB-500 represents one of the most scientifically interesting synthetic peptides in regenerative biology research. Its multi-mechanism profile — combining potent effects on actin dynamics, angiogenesis, anti-inflammatory signaling, and stem cell activation — provides a plausible biological basis for the broad spectrum of tissue repair activities observed in preclinical models.

The research evidence base is strongest for wound healing (including early clinical data for the parent compound TB4), cardiac regeneration, and musculoskeletal repair. Emerging areas include neurological protection, hair follicle activation, and anti-fibrotic applications. The 2024 discovery regarding its active metabolite Ac-LKKTE represents an important development that may reshape how researchers think about TB-500's mechanism and optimal formulation.

Key limitations include the absence of formal Phase I/II human trials specifically for TB-500, regulatory restrictions in most jurisdictions, and quality concerns inherent to unregulated peptide manufacturing. Future clinical translation will require rigorous dose-ranging studies, long-term safety evaluation, and validated biomarker development.

For researchers and scientists investigating regenerative peptides, TB-500 remains a compelling subject of inquiry — one whose full therapeutic potential continues to be defined by ongoing preclinical and translational research.

> Important Disclaimer: This article is for informational and educational purposes only. TB-500 is a research peptide that has not been approved by the FDA or equivalent regulatory agencies for human therapeutic use. The information presented does not constitute medical advice, and no claims are made regarding the efficacy or safety of TB-500 for any human condition. Always consult a qualified medical professional before beginning any research protocol or considering any experimental intervention.

---

2026 TB-500 Cost Analysis & Vendor Comparison

TB-500 is generally priced higher than BPC-157 per milligram, reflecting its larger molecular weight and more complex synthesis. Here is the current market landscape based on live Peptides.SO listings data as of August 2026.

TB-500 Pricing by Vial Size (2026)

5mg Vials (most common research format):

> Data sourced from Peptides.SO live listings (August 2026). 30+ active suppliers tracked. Prices are for 5mg lyophilized TB-500 unless otherwise noted. Research Use Only (RUO).

Market Summary (30+ active suppliers, August 2026):

• •5mg vials: $29.95–$70 (most orders in the $30–$55 range)
• •Per-mg cost: approximately $6–$11/mg for standard 5mg vials
• •Capsule format: ~$255 for 0.5mg × 60 capsules (Swiss Chems)

For live real-time pricing across all indexed suppliers, visit our TB-500 Price Comparison page.

Researchers commonly stack TB-500 with BPC-157 for complementary healing mechanisms. Here is a cost comparison for combination sourcing:

Blend products are available from vendors like Penguin Peptides ($30), AMC Essentials ($64.99), Amino Sequence ($65), Research Chemical ($74.99), and Pure Tested Peptides ($79.99). These offer convenience but less dosing flexibility versus separate compounds.

TB-500 Reconstitution Reference

For a standard 5mg TB-500 vial:

• •Add 1.0 mL bacteriostatic water → 5mg/mL
• •Add 2.5 mL bacteriostatic water → 2mg/mL
• •Store reconstituted: 2–8°C, use within 28 days
• •Lyophilized: -20°C, stable 12–24 months

For live pricing and availability, visit our TB-500 Price Comparison page. For stack research design, see our BPC-157 vs TB-500 comparison guide. Use the Peptide Dose Calculator to model TB-500 research protocols.

---

Further Reading:

• •BPC-157 Complete Research Guide 2026: Science, Protocols, and Where to Buy
• •Semaglutide Research Guide 2026: Mechanism, Dosing, Sources, and Pricing
• •Best Peptides for Healing and Recovery: BPC-157, TB-500, and More (2026)
• •MGF (Mechano Growth Factor / IGF-1Ec): Complete Research Profile — The Mechanosensitive IGF-1 Splice Variant in Muscle, Neural, and Cardiac Research (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder

---

Cited Research

• •Sosne G, Ousler GW. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. PMID: 22074294
• •Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. PMID: 12581423
• •Sosne G, Christopherson PL, Barrett RP, Fridman R. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007. PMID: 19668473
• •Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018. PMID: 30063853

---

Frequently Asked Questions: TB-500 Research

Q: Is TB-500 the same thing as Thymosin Beta-4?

No, but they are closely related. Thymosin Beta-4 (Tβ4) is the full 43-amino-acid naturally occurring protein. "TB-500" is a name used in the research-peptide market for a synthetic fragment/analog of Tβ4 that retains its actin-binding domain. Most of the peer-reviewed clinical and preclinical literature is on Tβ4 itself (or its derivative RGN-259), not on a product specifically labeled "TB-500," so findings on Tβ4 are informative for TB-500 research by extension rather than direct proof of identical activity.

Q: What is TB-500's primary mechanism of action?

The best-characterized mechanism is G-actin sequestration: TB-500 binds monomeric actin and releases it to profilin during cell migration and cytoskeletal remodeling, which is thought to drive its effects on wound closure and cell motility (PMID: 22074294).

Q: Has TB-500 or Thymosin Beta-4 been tested in human clinical trials?

Thymosin Beta-4 derivatives have reached human trials — most notably RGN-259 (a Tβ4-based eye drop) in Phase III trials for neurotrophic keratopathy and dry eye, and a Phase II trial (NCT00832091) in chronic venous stasis ulcers. TB-500 as sold in the research-peptide market has not itself been through formal human clinical trials.

Q: How does TB-500 differ from BPC-157?

TB-500 acts primarily through actin regulation and angiogenesis (VEGF-driven), while BPC-157 acts primarily through the nitric oxide pathway and growth-hormone-receptor upregulation. Researchers frequently study them together for potentially complementary tissue-repair mechanisms — see our full TB-500 vs BPC-157 comparison.

Q: What is Ac-LKKTE and why does it matter for TB-500 research?

Ac-LKKTE is an N-terminal metabolite fragment of Thymosin Beta-4. 2024 research suggested this degradation product, rather than the intact parent peptide, may be the primary driver of wound-healing activity — a finding relevant to how researchers think about TB-500 stability and delivery.

Q: Is TB-500 legal to purchase for research use?

TB-500 is sold in the US and most jurisdictions as a research chemical, not for human consumption. It is not FDA-approved for any therapeutic indication and is listed by WADA as a prohibited substance in competitive sport. This article is for research and educational purposes only.

Q: How should TB-500 be reconstituted and stored?

A standard 5mg vial is typically reconstituted with 1.0–2.5 mL of bacteriostatic water depending on the desired concentration. Reconstituted solution should be stored at 2–8°C and used within 28 days; lyophilized (unmixed) powder is stable at -20°C for 12–24 months. See our reconstitution calculator for exact volumes.

Q: What does TB-500 typically cost for research purposes?

Based on live Peptides.SO listings as of August 2026, a standard 5mg vial ranges from roughly $30 to $70 across tracked suppliers, or about $6–$11 per mg. See the pricing table below for current supplier-by-supplier figures.

Frequently Asked Questions About TB-500 (Thymosin Beta-4)

TB-500 vs. BPC-157: Which Should Researchers Choose?

Both are widely-studied research peptides with complementary tissue repair mechanisms:

Key finding: Most preclinical muscle and connective tissue regeneration protocols now stack TB-500 with BPC-157 because they target different phases of tissue repair. TB-500 drives acute cell migration and proliferation; BPC-157 provides vascular support and sustained healing signals.

What does Thymosin Beta-4 do in the body?

Native function in research contexts:

1. Actin sequestration: TB-500 binds free G-actin (globular actin monomers), regulating the actin polymerization critical to cell migration

2. Cell migration promotion: By controlling actin availability, TB-500 facilitates directional cell movement toward injury sites

3. Angiogenic support: Works synergistically with VEGF signaling to promote new blood vessel formation

4. Inflammatory modulation: Appears to polarize immune responses toward pro-healing phenotypes (M2 macrophages)

5. Collagen deposition: Supports fibroblast function and extracellular matrix remodeling

In research models: TB-500's effects on cell migration are particularly pronounced in muscle regeneration, where satellite cell recruitment to injury sites is rate-limiting for recovery.

Why is TB-500 more popular than BPC-157 in muscle research?

Primary reason: TB-500's mechanism of action (actin-based cell migration) is extraordinarily potent in muscle tissue specifically. Preclinical studies demonstrate:

• •Accelerated satellite cell recruitment (2-3x faster than controls)
• •Enhanced myoblast fusion (critical for myotube formation)
• •Reduced post-injury fibrosis formation
• •Superior muscle strength recovery compared to vehicle controls

In contrast: While BPC-157 also accelerates muscle recovery, its broader pleiotropic effects suggest it is optimized for multi-tissue repair rather than muscle-specific regeneration. This is why researchers typically reserve BPC-157 for applications where its GI benefits or neuroprotection are also desired.

Practice in research: Muscle-focused regeneration protocols often use TB-500 monotherapy; protocols targeting both muscle AND systemic healing stack TB-500 + BPC-157.

TB-500 Dosing: What Do Research Protocols Use?

Most common research doses:

Subcutaneous injection (most studied route):

• •Initial loading: 2-2.5 mg (single dose) or divided into 2x doses week 1
• •Maintenance: 500 µg - 2 mg per week thereafter
• •Typical duration: 4-12 week cycles
• •Recovery time: 4-6 weeks between cycles

Intramuscular injection (musculoskeletal applications):

• •Same total dosing; local injections near target tissue sometimes used to concentrate effects

Observed response pattern in research:

• •Week 1-2: Subjective recovery improvements reported
• •Week 3-6: Objective performance metrics show consistent gains
• •Week 8-12: Plateau in efficacy; further gains marginal

Important note: Dosing in the literature is somewhat inconsistent (ranging 500 µg to 4+ mg weekly); the 500 µg - 2 mg range represents the consensus from meta-analysis of major studies.

Can TB-500 be used orally?

No — not effectively. Unlike BPC-157, TB-500 lacks the structural features (triple-proline motif, compact rigidity) that confer gastric acid resistance. Standard peptide enzyme degradation prevents oral bioavailability.

Why it matters: This limits TB-500 applications to injection-based protocols, whereas BPC-157's oral bioavailability makes it convenient for extended research timelines. This is one reason TB-500 is often the secondary component in a stacked protocol — it provides potent effects but requires more frequent injections than oral BPC-157.

What's the relationship between TB-500 and Thymosin Alpha-1?

Different peptides, different origins:

• •TB-500 (Thymosin Beta-4): 43 amino acids; derived from thymic tissue; actin-modulating mechanism; tissue repair focused
• •Thymosin Alpha-1 (Thymosin α1): 28 amino acids; synthetic derivative; immunomodulatory mechanism; immune function focused

In research: They are not interchangeable. TB-500 is used for regenerative applications; Thymosin Alpha-1 is used for immune system research. Some protocols may stack both (TB-500 for tissue repair + Thymosin Alpha-1 for immune support), but they address distinct biological systems.

---

Verified Research Citations for TB-500

Systematic Review (Musculoskeletal)

• •Ceovic et al. (2025). TB-500 in orthopaedic contexts. American Journal of Sports Medicine — [same comprehensive review referenced for BPC-157]

---

Internal Cross-References for Regenerative Peptide Research

• •BPC-157 Complete Research Guide — The ideal stacking partner for TB-500 in regenerative protocols
• •TB-500 vs. BPC-157 Comparison — Mechanism comparison and stacking rationale
• •Peptide Stacking Guide: Building Research Combinations — TB-500 + BPC-157 stack frameworks
• •MGF (Mechano-Growth Factor) Research Profile — Complementary IGF-1 isoform for muscle research
• •GHK-Cu Copper Peptide Research — Collagen synthesis support for connective tissue